Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …

Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …

The T cell infiltrates that are formed in human cancers are a modifier of natural disease
progression and also determine the probability of clinical response to cancer …

Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 editing of
immune checkpoint genes could improve the efficacy of T cell therapy, but the first necessary …

CD8+ T cells specific for cancer cells are detected within tumours. However, despite their
presence, tumours progress. The clinical success of immune checkpoint blockade and …

To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer
regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors …

Identifying tumor antigen-specific T cells from cancer patients has important implications for
immunotherapy diagnostics and therapeutics. Here, we show that CD103+ CD39+ tumor …